GSK divests thrombosis brands, related manufacturing to Aspen for £700m
This article was originally published in Scrip
GlaxoSmithKline has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the related Notre-Dame de Bondeville (NDB) manufacturing site, to Aspen – a South African pharmaceuticals company – for £700m in cash, of which £100m relates to inventory.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.